This page features all press releases issued during the ESTRO 2025 Congress, highlighting key clinical advances in radiation oncology.
Explore the latest findings in prostate, lung, gynaecological, anal, and rectal cancer treatment, based on pivotal trials and new approaches presented at the congress.
Prostate Cancer
Two-week radiotherapy proven as safe and effective as standard eight-week course for prostate cancer
10-Year results from a phase III trial
- Read the full press release: LINK
Anal and Rectal Cancer
Five major advances in anal and rectal cancer treatment with radiotherapy
A new era of organ-preserving options
- Read the full press release: LINK
Each of the five studies featured in this overview is detailed in an individual press release below:
- Clinical trial demonstrates efficacy of lower dose, shorter course radiotherapy for early-stage anal cancer and could reduce healthcare burden
Read the press release > LINK
- STAR-TREC study shows successful organ preservation with chemoradiotherapy or short-course radiotherapy, reducing the need for surgery in early-intermediate stage rectal cancer patients
Read the press release > LINK
- New study shows immunotherapy and radiotherapy could help
more rectal cancer patients avoid surgery
Read the press release > LINK
- Immunotherapy combined with radiotherapy and chemotherapy reduces
the need for surgery in locally advanced rectal cancer
Read the press release > LINK
- Phase III clinical trial suggests benefits of short-course radiotherapy
with chemotherapy for locally advanced rectal cancer
Read the press release > LINK
Lung Cancer
Protecting the Heart During Lung Cancer Radiotherapy
New technique learns from every patient
- Read the full press release: LINK
Gynaecological Cancer
Personalised radiotherapy for endometrial cancer
Molecular profiling helps avoid overtreatment and tailor care for high-risk patients
- Read the full press release: LINK
Breast Cancer
FAST-Forward trial, strong ten-year reseults for 1 year breast radiotherapy